NASDAQ:KYMR
Kymera Therapeutics Inc. Stock News
$34.95
-0.650 (-1.83%)
At Close: May 17, 2024
Kymera: Data Derisks Platform, But I Will Wait For More
06:58pm, Monday, 23'rd Jan 2023
Kymera Therapeutics, Inc.'s KT-474 HS/AD data de-risked the IRAK4 protein degradation platform, as did Sanofi's partnering. However, more differentiating data seems to be needed in these indications a
All You Need to Know About Kymera Therapeutics, Inc. (KYMR) Rating Upgrade to Buy
01:33pm, Monday, 09'th Jan 2023
Kymera Therapeutics, Inc. (KYMR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
07:00am, Tuesday, 03'rd Jan 2023
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m
7 Perfect Presents to Gift Your 2023 Stock Portfolio
04:57pm, Wednesday, 21'st Dec 2022
New Year 2023 will see a continued tightening of monetary policy as the Federal Reserve attempts to rein in sky-high inflation. Following the 50 basis point rate hike in Dec., there are expectations t
Kymera (KYMR) Up on Positive Data From Phase I Study on KT-474
12:02pm, Thursday, 15'th Dec 2022
Kymera (KYMR) posts positive data from a phase I study on KT-474 for treating patients with hidradenitis suppurativa and atopic dermatitis. Sanofi to advance KT-474 in phase II study.
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
01:44pm, Wednesday, 14'th Dec 2022
Business wins are shining the spotlight on these two companies.
Why Is Kymera Therapeutics (KYMR) Stock Up 20% Today?
11:08am, Wednesday, 14'th Dec 2022
What's trending in the pharmaceutical sector today? In a fresh press release, Kymera Therapeutics (NASDAQ: KYMR ) disclosed positive results from its clinical trial for a skin condition treatment the
Kymera Therapeutics Provides Webcast Information for December 14 Investor Event
07:00am, Thursday, 01'st Dec 2022
Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline
Kymera: Upcoming Trial Data Will Make Or Break The Company
11:46am, Tuesday, 08'th Nov 2022
Kymera has some critical trial data coming up this quarter. Other IRAK4 inhibitors have been having trouble.
Kymera Therapeutics, Inc. (KYMR) Q3 2022 Earnings Call Transcript
01:27am, Sunday, 06'th Nov 2022
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Nello Mainolfi - Founder & Chief Executive Officer Jared Gollob - Chief Medic
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates
09:47am, Thursday, 03'rd Nov 2022
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -12.86% and 41.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th
Kymera Therapeutics to Report Third Quarter 2022 Results on November 3
07:30am, Thursday, 20'th Oct 2022
Company also presenting at upcoming investor conferences Company also presenting at upcoming investor conferences
Dosing in KT-474 Phase 1 HS and AD patient cohort (Part C) complete
Insiders Buying Ecolab, Kymera Therapeutics And This Consumer Cyclical Stock
09:15am, Wednesday, 24'th Aug 2022
Although US stocks closed mostly lower on Tuesday, there were a few notable insider trades.
Kymera Therapeutics, Inc. (KYMR) CEO Nello Mainolfi on Q2 2022 Results - Earnings Call Transcript
02:11am, Wednesday, 10'th Aug 2022
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Nello Mainolfi - Founder & CEO Jared Gollob - Chief Medical Officer Bruce Jacob
